Additionally, the second of the clinical trials mentioned above showed a higher rate of complete pathological responses among patients with a higher proportion of Ki-67-positive or PD-L1- and SOX10-positive melanoma cells in the baseline tumor samples [16]. Here, CD274 is linked to neoplasm.